Bioneer

Bioneer Corporation is a Korea-based biotechnology company operating in genetic research, molecular diagnostics, probiotics and RNA interference (RNAi) drug development. It provides services including oligonucleotide (DNA/RNA) synthesis, Sanger sequencing, CRISPR gene and mRNA work, gene expression analysis, protein synthesis, monoclonal antibody production, and MALDI-TOF and LC/HR MS analysis. Its product catalogue spans gene amplification, nucleic acid preparation and purification, cloning, ladders and markers, cell-free protein expression, yeast engineering, buffers and chemicals, instruments, and diagnostic lines for veterinary, aquatic, food and environmental applications as well as human pathogens.

Featured products include the EcoQprep mRNA kit, which uses Oligo(dT)-based magnetic beads for selective mRNA purification; the ExiCycler V5 real-time PCR instrument, which analyses up to six targets simultaneously in a single run; and ExiProgen, a cell-free expression system that automates the workflow from DNA to synthesised and purified protein. In addition to research products, the company sells body-fat-reducing lactic acid bacteria in the probiotics field and reagents, kits and instruments for gene extraction, amplification and quantitative analysis used in molecular diagnostics.

Bioneer also runs a gene synthesis business built on in-house oligonucleotide synthesis, offering gene synthesis, rapid gene synthesis and AccuGeneBlock DNA fragment services with 100% sequence guarantee verified by automated Sanger sequencing, plus cloning, mutagenesis, mRNA synthesis and integrated gene-to-protein services. It markets AI-based design software, including GeneCrafter for codon optimisation, IVTDesigner and UTRDesigner for mRNA and UTR design, CircularDesigner for circular RNA, SaRNADesigner for self-amplifying RNA, and a Unified Protein Engineering Platform for protein variant, recombinant and de novo design.

Business model

Bioneer sells research reagents, kits, consumables and laboratory and diagnostic instruments, and provides fee-based synthesis and analysis services (gene synthesis, cloning, mutagenesis, mRNA synthesis, sequencing, protein expression and MS analysis) ordered through its online shop, alongside probiotics products and an RNAi therapeutics development program.

Revenue is generated from product sales and per-order service pricing; gene synthesis, for example, is priced by base pair (e.g. KRW 250/bp above 400 bp, KRW 100,000 for genes up to 400 bp) with additional fees for alternative vectors, subcloning and plasmid quantity increases.

Traction

The company reported approximately 392 employees. Quarterly results reported in 2025 included first-quarter operating profit of KRW 4.3 billion (up 56.4% year on year), second-quarter operating profit of KRW 5.6 billion and third-quarter operating profit of KRW 3 billion, both swings to profit from year-earlier losses; a first-quarter 2026 operating loss of KRW 760 million was subsequently reported.

Latest developments

First-quarter 2026 results reported an operating loss of KRW 760 million. As of the end-of-day quote on 2026-08-28, shares traded at KRW 8,310, down 34.82% year to date. The company promotes AI-driven design software for gene, mRNA, circular RNA, self-amplifying RNA and protein engineering applications.